The PennZone

  • Home
  • Business
  • Health
  • Financial
  • Construction
  • Automotive
  • Technology
  • Music
  • Books

Olympus Acquires Veran Medical Technologies, Inc.
The PennZone/10102444

Trending...
  • BumblebeeSmart Introduces Rounded Busy Board Set for Preschoolers
  • Dispelling Holiday Suicide Myth: CDC Data Shows Suicide Rates Lowest in December; International Survivors of Suicide Day Emphasizes Need for Action
  • New Smile Now Introduces RAYFace 3D Scanner to Advance Digital Surgery
CENTER VALLEY, Pa. and TOKYO, Dec. 30, 2020 /PRNewswire/ -- Olympus Corporation today announced that it has finalized the acquisition of Veran Medical Technologies, Inc. (VMT), a leading provider of advanced medical devices specializing in interventional pulmonology, following the definitive agreement the two companies signed December 4, 2020. With this acquisition by Olympus subsidiary Olympus Corporation of the Americas (OCA), Olympus gains VMT's global sales network, marketing, manufacturing, R&D, and other functions to expand the Olympus respiratory product portfolio.

Lung cancer is the leading cause of cancer-related deaths globally.1 With increased awareness and more lung cancer screenings using low-dose computed tomography (CT), the need for definitive diagnosis of lesions in the peripheral regions of the lungs by tissue biopsy is expected to increase. VMT's SPiN Thoracic Navigation System® and related devices are specifically designed to help physicians navigate to, localize, and sample peripheral pulmonary lesions. Together with the existing Olympus respiratory portfolio that includes radial endobronchial ultrasound (EBUS) and thin bronchoscopes, VMT's navigational system and related devices provide a powerful combination of imaging, access and precision for pulmonologists seeking to diagnose and determine the stage of a patient's lung cancer.

More on The PennZone
  • Paylode Acquired by Moved to Power the Next Generation of Ancillary Revenue Automation
  • Global Preschool Giants Unite to Celebrate the 12th Anniversary of Badanamu's Hit Song "Ponytail"
  • America's Leading Annuity Expert Carlton Cap Averil II Joins Tom Hegna on "Financial Freedom with Tom Hegna"
  • Cheeron Partners with CRCC to Support Shanghai East Railway Station
  • MiBoxer Shines at 2025 Hong Kong International Lighting Fair, Intelligent Lighting Solutions Acclaimed by Global Clients

"We are very excited about the synergies this acquisition creates. With the deal now closed, as one company we are able to combine Olympus' expertise and clinical history in minimally invasive technology with the innovation in navigation systems of Veran Medical Technology to improve workflow and patient care in lung cancer," said Lynn Ray, Vice President and General Manager of the Global Respiratory Business Unit for Olympus Corporation. "Olympus is committed to providing the medical community with the best tools possible to use in their fight against cancer. With the advent of EBUS-guided transbronchial needle aspiration (EBUS-TBNA) in 2004, Olympus brought patients the benefit of more accurate diagnosis and staging, to improve patient outcomes and care. We are thrilled to be at the forefront of development in this rapidly evolving area of respiratory care."

The acquisition will provide immediate incremental revenue and an experienced sales team within the U.S. market. VMT's advanced and proven navigation technology, together with Olympus' respiratory portfolio, strengthens and enhances Olympus' global position as a medical technology innovator.

As part of its current Corporate Strategy, Olympus vowed to "focus and scale" its Therapeutic solutions Division (TSD). To accelerate the process and provide greater agility, Olympus made OCA the TSD headquarters, recognizing the significant growth opportunities in North America. Olympus also identified three core medical fields to prioritize and has since focused on gastroenterological endotherapy devices, urological devices, and respiratory devices. The VMT acquisition is centered on respiratory devices and will position Olympus as a leader in this field.

More on The PennZone
  • Anern Launches the AN-SLZ2 Smart Integrated Solar Street Light
  • "Nikko Kitchen," Tochigi Prefecture's New Gourmet Eatery, has Opened Near Tobu Nikko Station
  • Michael Gi Delivers Inspiring New Gospel Releases That Lift Hearts and Honor Legacy
  • Ashley Wineland To Release Scorching Single and Film Noir Cinematic Video for 'Love Letter'
  • Chuckie F. Mahoney Memorial Foundation Funds Program to Curb Cyber Bullying in Burgettstown Schools

For additional information, please refer to our corporate disclosure, "Notice regarding acquisition of Veran Medical Technologies, Inc. in the United States."

(available at: https://www.olympus-global.com/news/ir/2020/)

1 WHO data:  https://www.who.int/news-room/fact-sheets/detail/cancer

About Olympus' Therapeutic Solutions Division
In its Therapeutic Solutions business, Olympus uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients. Starting with its early contributions to the development of the polypectomy snare, Olympus' Therapeutic Solutions portfolio has grown to include an array of surgical energy devices and a wide range of instruments to help prevent, detect, and treat disease. For more information, visit www.olympus-global.com.

SOURCE Olympus

Related Links

http://www.olympus.com/
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • 2026 NBA Mock Draft: New Wave of Franchise Talent Emerges in Early Lottery Projections
  • Bad Bunny Leads 2026 Grammys Album of the Year Odds, Lady Gaga Emerges as Top Challenger
  • Metro Detroit teen Lola Winters turns viral TikTok fame into a sold-out clothing brand
  • ReedSmith® Celebrates Innovative Founders at TCVN's Survivor™ XII at SoCal Startup Day
  • The global race for next-gen precious metals recovery is accelerating: $AABB is positioning itself with it's Revolutionary rGO Gold Recovery System
  • NorthSky Celebrates One-Year Anniversary
  • Free At Last Bail Bonds Gives Back Through Major Holiday Food Distribution Efforts Across Metro Atlanta
  • Discover Elevated Living - Preview the Stunning New Townhome Collection
  • TownePlace Suites Prescott Valley, AZ Opens
  • SIX7 Introduces Olfactory Neurodesign™ — The First Fragrance System Engineered to Influence Emotion, Memory, and Desire at the Neural Level
  • GetKuwa emerging as GCC's #1 trusted online supplement marketplace as shoppers across UAE, Saudi Arabia, Kuwait, Qatar & Oman seek authenticity
  • Uk Financial Ltd Provides Investors Of Maya Preferred & Mayacat Instructions For Upcoming First Ever Listing Of Both Erc-3643 "SEC-Ready" Tokens
  • Kaufman Development and Daniel Kaufman Ventures Announce Strategic Expansion Into Data Centers and AI Infrastructure Across the United States
  • Bent Danholm Lists Modern Lakefront Estate in Winter Garden's Twinwaters Community
  • Operational Agility in High Demand: FOCUS Expands to Serve a Changing Insurance Market
  • Bahamas Import Assistant Launches Same-Day Pet Permit Service Under BAHFSA's 2024 Expansion
  • Liftoff Enterprises Launches Liftoff Spotlight,™ A Nationally Broadcast Platform Turning Conversations Into Revenue
  • From November 24th to 27th, Fuqing Invites You to Join Us at BIG 5 to Jointly Build a New Future for Middle Eastern Architecture
  • Dispelling Holiday Suicide Myth: CDC Data Shows Suicide Rates Lowest in December; International Survivors of Suicide Day Emphasizes Need for Action
  • Stratum Nutrition's OVOLUX™ Named 2025 "Collagen Ingredient of the Year" by Beauty Innovation Awards

Popular on PennZone

  • J French's #1 Album "I Don't Believe in Bad Days" Enters the Grammy Conversation
  • 'Wild Hermit Wellness' Has Achieved Bestseller Status in Just 2 Months Since Launch Of Organic Skincare Line
  • Bookmakers Review Releases 2028 Democratic Nominee Betting Odds: Newsom Leads Early Field
  • Literary fiction novel- 'Skylark' wins Bronze Medal
  • Assent Recognizes Manufacturers for Leading Supply Chain Sustainability Programs
  • Kilmer Construction Announces Seasonal Savings on Home Improvements in Northeastern PA
  • Local Boyertown Auto Shop Announces Expansion Due to Overwhelming Customer Demand
  • Taboo: The Lost Codes of Men — A Bold New Book Confronting the Crisis of Modern Manhood
  • Dongsheng's Titanium Recycling Business Enters Aerospace Sector by 2025
  • Frost Locker: New Research Reveals Mild Cold—Not Extreme Cold—Delivers Real Health Benefits of Cold Therapy

Similar on PennZone

  • Tax Fears and Political Volatility Drive Wealthy UK Residents to Consider Leaving, La Vida Survey Shows
  • Kaltra Removes Size Barriers for Microchannel Coils with Fully Integrated Large-MCHE Production
  • Why Gourmet Steaks Are the Perfect Holiday Gift
  • Inframark Expands Its Specialized Automation and Intelligence Capabilities, Adds Dmytryka Jacobs Engineers
  • CRH Healthcare Opens 100th Urgent Care Clinic with Second Peachtree Immediate Care Location in Covington
  • 2026 NBA Mock Draft: New Wave of Franchise Talent Emerges in Early Lottery Projections
  • ReedSmith® Celebrates Innovative Founders at TCVN's Survivor™ XII at SoCal Startup Day
  • Free At Last Bail Bonds Gives Back Through Major Holiday Food Distribution Efforts Across Metro Atlanta
  • Uk Financial Ltd Provides Investors Of Maya Preferred & Mayacat Instructions For Upcoming First Ever Listing Of Both Erc-3643 "SEC-Ready" Tokens
  • Bahamas Import Assistant Launches Same-Day Pet Permit Service Under BAHFSA's 2024 Expansion
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us